The mutation rate of SARS-CoV-2 is highly variable between sites and is influenced by sequence context, genomic region, and RNA structure.

Publication date: Jun 06, 2025

RNA viruses like SARS-CoV-2 have high mutation rates, which contribute to their rapid evolution. Mutation rates depend on mutation type and can vary between sites in a virus’s genome. Understanding this variation can shed light on the mutational processes at play, and is crucial for quantitative modeling of viral evolution. Using millions of SARS-CoV-2 full-genome sequences, we estimate rates of synonymous mutations for each mutation type and examine how much these rates vary between sites. We find a surprisingly high level of variability. A substantial fraction of this variability can be explained by local sequence context, genomic region, and RNA secondary structure. We estimate fitness effects of each mutation based on the number of times it actually occurs versus the number of times it is expected to occur based on a model of the above features. We identify small regions of the genome where synonymous or noncoding mutations occur much less often than expected, indicative of strong purifying selection on the RNA sequence independent of protein sequence. Overall, this work expands our basic understanding of SARS-CoV-2’s evolution by characterizing the virus’s mutation process at the level of individual sites and uncovering several striking mutational patterns that arise from unknown mechanisms.

Open Access PDF

Concepts Keywords
Fitness COVID-19
Genome Evolution, Molecular
Mutational Genome, Viral
Rapid Humans
Viral Mutation
Mutation Rate
Nucleic Acid Conformation
RNA, Viral
RNA, Viral
SARS-CoV-2
Silent Mutation

Semantics

Type Source Name
disease MESH mutation rate
disease IDO protein
disease IDO process
drug DRUGBANK Coenzyme M
pathway REACTOME Reproduction
drug DRUGBANK Hexocyclium
disease IDO host
disease MESH oxidative damage
disease IDO site
disease IDO history
drug DRUGBANK Amino acids
drug DRUGBANK Acetylcholine
disease IDO quality
drug DRUGBANK Aspartame
disease MESH uncertainty
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Piroxicam
drug DRUGBANK L-Valine
disease IDO replication
drug DRUGBANK Trestolone
drug DRUGBANK Esomeprazole
pathway KEGG Viral replication
pathway REACTOME Translation
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Stavudine
drug DRUGBANK Fenamole
disease MESH infection transmission
disease MESH COVID 19 pandemic
disease IDO cell
drug DRUGBANK Flunarizine
pathway KEGG Ribosome
drug DRUGBANK Alprostadil
disease IDO nucleic acid

Original Article

(Visited 1 times, 1 visits today)